Cantor Fitzgerald Reiterates Overweight Rating for Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $65.00 price objective on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 78.77% from the stock’s current price.

Separately, Lifesci Capital reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $85.71.

Structure Therapeutics Stock Up 0.5 %

Structure Therapeutics stock opened at $36.36 on Thursday. The company has a market cap of $1.69 billion and a price-to-earnings ratio of -43.81. The firm’s fifty day moving average is $40.55 and its 200 day moving average is $48.47. Structure Therapeutics has a 52-week low of $21.79 and a 52-week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. On average, equities research analysts anticipate that Structure Therapeutics will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. TrueMark Investments LLC raised its stake in shares of Structure Therapeutics by 13.5% in the first quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock valued at $1,281,000 after acquiring an additional 3,562 shares during the period. Wellington Management Group LLP grew its holdings in shares of Structure Therapeutics by 404.0% in the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after purchasing an additional 3,504,747 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Structure Therapeutics by 498.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 427,735 shares of the company’s stock worth $17,434,000 after purchasing an additional 356,302 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in shares of Structure Therapeutics in the fourth quarter worth about $475,000. Finally, FIL Ltd grew its holdings in shares of Structure Therapeutics by 8.1% in the fourth quarter. FIL Ltd now owns 9,304 shares of the company’s stock worth $379,000 after purchasing an additional 695 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.